Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A P/E Ratio

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A (FBIOP) currently reports a P/E ratio of 0.83. That is below the Healthcare sector average of 25.75. Use the charts on this page to explore Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's P/E ratio history and peer comparisons.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's P/E ratio of 0.83 is lower than the Healthcare sector average of 25.75. That is roughly 96.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's market price to a fundamental measure such as earnings, sales, or book value. At 0.83, FBIOP can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 0.83, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.75. From there, open related valuation or income-statement pages for Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A, and consider following FBIOP for alerts when major investors trade the stock.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A is classified in the Healthcare sector. On P/E ratio, it currently shows 0.83 versus a sector average near 25.75. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FBIOP with unrelated industries.